Literature DB >> 18794216

Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology.

Scott Ramsey1, John Scoggins.   

Abstract

OBJECTIVE: Members of the International Committee of Medical Journal Editors require, as a condition of consideration for publication, that all clinical trials be registered in a public trials registry. We evaluated the proportion of registered trials that are published in the peer-reviewed literature.
METHODS: After downloading the contents of the National Institutes of Health's ClinicalTrials.gov registry, we used key words to identify trials in oncology. We then evaluated the proportion of trials that had been published in journals listed in PubMed.gov. Among trials with published results, we determined the proportion that reported positive versus negative results.
RESULTS: Among the 2,028 trials meeting the inclusion criteria, 17.6% were available in PubMed. Twenty-one percent of the trials registered before September 1, 2004 were published, compared with 11.9% of those registered after this date. Trials sponsored by clinical trial networks published the greatest proportion of registered studies (59.0%); studies sponsored by industry published the fewest (5.9%). Among published studies, 64.5% reported the results as positive findings.
CONCLUSIONS: Less than one in five studies in cancer that are registered with clinicaltrials.gov have been published in peer-reviewed journals. Research sponsors, researchers, and journal editors should redouble their efforts to encourage publication of registered clinical trials in oncology.

Entities:  

Mesh:

Year:  2008        PMID: 18794216      PMCID: PMC2675281          DOI: 10.1634/theoncologist.2008-0133

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  17 in total

1.  Public registration of clinical trials.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

2.  Publication bias and dissemination of clinical research.

Authors:  C B Begg; J A Berlin
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

3.  Evidence of publication bias in clinical trials of biotherapies for solid tumors.

Authors:  Alessandro Ottaiano; Giuseppe Castello; Paolo Antonio Ascierto
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

4.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

5.  Publication bias: evidence of delayed publication in a cohort study of clinical research projects.

Authors:  J M Stern; R J Simes
Journal:  BMJ       Date:  1997-09-13

6.  Publication bias and clinical trials.

Authors:  K Dickersin; S Chan; T C Chalmers; H S Sacks; H Smith
Journal:  Control Clin Trials       Date:  1987-12

7.  Publication bias: the case for an international registry of clinical trials.

Authors:  R J Simes
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

8.  Registering clinical trials.

Authors:  Kay Dickersin; Drummond Rennie
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

10.  A taxpayer-funded clinical trials registry and results database.

Authors:  Erick H Turner
Journal:  PLoS Med       Date:  2004-12       Impact factor: 11.069

View more
  32 in total

1.  The importance of doing trials right while doing the right trials.

Authors:  David M Dilts; Steven K Cheng
Journal:  Clin Cancer Res       Date:  2011-11-09       Impact factor: 12.531

2.  Understanding commonly encountered limitations in clinical research: an emergency medicine resident's perspective.

Authors:  Christopher W Jones; Timothy F Platts-Mills
Journal:  Ann Emerg Med       Date:  2011-08-04       Impact factor: 5.721

Review 3.  mAbs: a business perspective.

Authors:  Pablo A Scolnik
Journal:  MAbs       Date:  2009-03-21       Impact factor: 5.857

4.  Can web 2.0 reboot clinical trials?

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2009-10       Impact factor: 54.908

5.  Perspectives on the development of imatinib and the future of cancer research.

Authors:  Brian J Druker
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

6.  [From the design of use study to the assessment of the benefit: with or without pharmaceutical industry?].

Authors:  Franz Porzsolt
Journal:  Med Klin (Munich)       Date:  2011-01-16

7.  Precision and negative predictive value of links between ClinicalTrials.gov and PubMed.

Authors:  Vojtech Huser; James J Cimino
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

8.  Obstacles to researching the researchers: a case study of the ethical challenges of undertaking methodological research investigating the reporting of randomised controlled trials.

Authors:  Joanne E McKenzie; G Peter Herbison; Paul Roth; Charlotte Paul
Journal:  Trials       Date:  2010-03-21       Impact factor: 2.279

9.  Result publication of Chinese trials in World Health Organization primary registries.

Authors:  Xuemei Liu; Youping Li; Senlin Yin; Shangqi Song
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

10.  Association of trial registration with the results and conclusions of published trials of new oncology drugs.

Authors:  Nicolas Rasmussen; Kirby Lee; Lisa Bero
Journal:  Trials       Date:  2009-12-16       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.